Literature DB >> 11877309

Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia.

Milvia Casato1, Cristina Mecucci, Vincent Agnello, Massimo Fiorilli, Glenn B Knight, Caterina Matteucci, Lei Gao, Jonathan Kay.   

Abstract

A patient with type II cryoglobulinemic vasculitis and hepatitis C virus (HCV) infection presented with a leukemiclike proliferation of B cells bearing marginal zone B-cell phenotypic markers. A partial trisomy 3 (bands 3q11-29) and overexpression of Bcl-2 without t(14;18) translocation was detected in the monoclonal B cells that were classic rheumatoid factor-producing B cells bearing the WA cross-idiotype. Treatment with interferon-alpha produced a complete clinical remission and synchronous marked decreases in viremia and monoclonal B-cell prevalence. This is the first report of partial trisomy 3 and Bcl-2 overexpression in type II cryoglobulinemic vasculitis associated with HCV infection. Further studies of HCV-infected patients with and without type II cryoglobulinemia are required to determine the prevalence and possible physiologic and/or pathophysiologic significance of these findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877309     DOI: 10.1182/blood.v99.6.2259

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Hepatitis C virus and lymphoma.

Authors:  D S Viswanatha; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

2.  Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration.

Authors:  Li-Juan Su; Guang-Wei Ding; Zhi-Li Yang; Shou-Bing Zhang; Yu-Xiu Yang; Cun-Shuan Xu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 3.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

4.  Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Authors:  Chuan-ging Wu; Anuradha Budhu; Sheng Chen; Xiaoling Zhou; Nicholas C Popescu; Kristoffer Valerie; Xin Wei Wang
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

Review 5.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

6.  Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls.

Authors:  Gabriella Bianchettin; Claudia Bonaccini; Romina Oliva; Anna Tramontano; Agostino Cividini; Milvia Casato; Giampaolo Merlini; Enrico Silini; Mario U Mondelli
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

Review 7.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Rashidah M Green; Svetlana Marukian; Andrew H Talal; Gerond V Lake-Bakaar; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

Review 9.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

10.  Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells.

Authors:  Zania Stamataki; Claire Shannon-Lowe; Jean Shaw; David Mutimer; Alan B Rickinson; John Gordon; David H Adams; Peter Balfe; Jane A McKeating
Journal:  Blood       Date:  2008-10-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.